| New from NCI |
| How Imatinib Transformed Leukemia Treatment and Cancer Research |
 |
|
Learn about the NCI-supported discoveries that led to the development of imatinib (Gleevec). These discoveries helped establish a new group of drugs known as targeted therapy that has changed the treatment of cancer. |
| Video—Introduction to Adolescent and Young Adult Cancers |
 |
|
This video covers basic facts about cancer in adolescents and young adults and discusses the unique challenges these patients face. |
Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers
Scientists have struggled to come up with a simple test to detect endometrial and ovarian cancers early, when they are most likely to respond to treatment. Can a liquid biopsy test called PapSEEK change that? |
| Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer |
 |
|
Results from a large clinical trial testing a combination of the immunotherapy pembrolizumab (Keytruda) and chemotherapy in patients newly diagnosed with metastatic lung cancer may change clinical practice. |
Does Muscle Mass Affect Cancer Survival?
Read about a recent study in which researchers measured muscle mass in women with breast cancer and tracked its connection to survival. |
New Option for Women with Recurrent Ovarian Cancer
The Food and Drug Administration (FDA) recently approved a new PARP inhibitor for women with ovarian cancer who meet certain criteria. Learn about PARP inhibitors and why they are helpful in treating this disease.
|
| PDQ Summary Updates |
Non-Small Cell Lung Cancer Treatment
We’ve revised our PDQ summary on non-small cell lung cancer (NSCLC) with updates to the tests used to diagnose and stage the disease and to the treatments used for different stages.
|
| Drug Information Updates |
Ipilimumab Approved for Kidney Cancer
We’ve updated our drug information summary with a recent FDA approval. Ipilimumab (Yervoy) is now approved to be used with nivolumab to treat renal cell carcinoma, which is a type of kidney cancer. |
Nivolumab Combination in Kidney Cancer
Our updated drug information summary on nivolumab (Opdivo) includes the FDA’s recent approval of the drug for use with ipilimumab as a first-line therapy for renal cell carcinoma. |
Osimertinib Use in Lung Cancer
We’ve updated our drug information summary to include FDA’s expanded approval for osimertinib (Tagrisso) in NSCLC. The drug is now approved as a first-line treatment in certain patients with metastatic NSCLC. |
Tocilizumab for Cytokine Release Syndrome
We've added a new drug summary for tocilizumab (Actemra), which was approved by FDA to treat cytokine release syndrome (CRS) caused by CAR T-cell therapy. CRS is a severe side effect that can occur with some types of immunotherapy. |
